XML 82 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1

Acquisitions and Divestiture (Asset Acquisitions) (Details) - USD ($) $ in Millions	1 Months Ended																	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Aug. 31, 2021	Jul. 31, 2021	May 31, 2021	Mar. 31, 2021	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Jun. 30, 2020	May 31, 2020	Mar. 31, 2020	Sep. 30, 2019	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Acquired IPR&D charges																			$ 874.9	$ 660.4	$ 239.6
Precision Biosciences, Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges							$ 107.8
Merus N.V.
Business Acquisition [Line Items]
Acquired IPR&D charges							46.5
Asahi Kasei Pharma Corporation
Business Acquisition [Line Items]
Acquired IPR&D charges							$ 20.0
Rigel Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges						$ 125.0
MiNA Therapeutics Limited
Business Acquisition [Line Items]
Acquired IPR&D charges					$ 25.0
Protomer Technologies Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges				$ 57.3
Kumquat Biosciences Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges				$ 55.0
Lycia Therapeutics, Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges			$ 35.0
ProQR Therapeutics N.V.
Business Acquisition [Line Items]
Acquired IPR&D charges		$ 26.7
QILU Regor Therapeutics Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges	$ 30.0
Foghorn Therapeutics Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges	316.6
Entos Pharmaceuticals Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges	$ 30.0
Sitryx Therapeutics Limited
Business Acquisition [Line Items]
Acquired IPR&D charges												$ 52.3
AbCellera Biologics Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges											$ 25.0	$ 25.0
Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)
Business Acquisition [Line Items]
Acquired IPR&D charges											20.0
Petra Pharma Corporation (Petra)
Business Acquisition [Line Items]
Acquired IPR&D charges											$ 174.8
Evox Therapeutics Limited
Business Acquisition [Line Items]
Acquired IPR&D charges										$ 22.0
Innovent Biologics, Inc. (Innovent)
Business Acquisition [Line Items]
Acquired IPR&D charges									$ 200.0
Disarm Therapeutics, Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges									$ 126.3
Fochon Pharmaceuticals, Ltd.
Business Acquisition [Line Items]
Acquired IPR&D charges								$ 40.0
AC Immune SA
Business Acquisition [Line Items]
Acquired IPR&D charges													$ 30.2				$ 96.9	$ 127.1
ImmuNext, Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges																$ 40.0
Avidity Biosciences, Inc.
Business Acquisition [Line Items]
Acquired IPR&D charges															$ 25.0
Centrexion Therapeutics Corporation
Business Acquisition [Line Items]
Acquired IPR&D charges														$ 47.5

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_MerusNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_QILURegorTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_EntosPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_ACImmuneSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_ImmuNextInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_AvidityBiosciencesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: